186 related articles for article (PubMed ID: 15722241)
21. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
22. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
Omari TI; Haslam RR; Lundborg P; Davidson GP
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
[TBL] [Abstract][Full Text] [Related]
23. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
[TBL] [Abstract][Full Text] [Related]
24. The role of pH monitoring in extraesophageal gastroesophageal reflux disease.
Ahmed T; Vaezi MF
Gastrointest Endosc Clin N Am; 2005 Apr; 15(2):319-31. PubMed ID: 15722244
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of esophageal function/pH in endoscopic therapy for gastroesophageal reflux disease.
Johnson DA
Gastrointest Endosc Clin N Am; 2005 Apr; 15(2):333-45. PubMed ID: 15722245
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic options in the treatment of nighttime gastroesophageal reflux.
Orr WC
Digestion; 2005; 72(4):229-38. PubMed ID: 16319458
[TBL] [Abstract][Full Text] [Related]
27. Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians.
Ahmed TF; Khandwala F; Abelson TI; Hicks DM; Richter JE; Milstein C; Vaezi MF
Am J Gastroenterol; 2006 Mar; 101(3):470-8. PubMed ID: 16542282
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
[TBL] [Abstract][Full Text] [Related]
29. Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.
Katz PO; Johnson DA
J Clin Gastroenterol; 2011 Oct; 45(9):748-54. PubMed ID: 21694609
[TBL] [Abstract][Full Text] [Related]
30. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.
Zerbib F; Roman S; Ropert A; des Varannes SB; Pouderoux P; Chaput U; Mion F; Vérin E; Galmiche JP; Sifrim D
Am J Gastroenterol; 2006 Sep; 101(9):1956-63. PubMed ID: 16848801
[TBL] [Abstract][Full Text] [Related]
31. The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment.
Richter JE
Gastroenterol Clin North Am; 2007 Sep; 36(3):577-99, viii-ix. PubMed ID: 17950439
[TBL] [Abstract][Full Text] [Related]
32. The use of proton pump inhibitors as a diagnostic test for gastroesophageal reflux disease.
Numans ME
Arch Intern Med; 2006 Jan; 166(2):247-8; author reply 248-9. PubMed ID: 16432097
[No Abstract] [Full Text] [Related]
33. A balancing view: Impedance-pH testing in gerd-limited role for now, perhaps more helpful in the future.
Shay S
Am J Gastroenterol; 2009 Nov; 104(11):2669-70. PubMed ID: 19888232
[No Abstract] [Full Text] [Related]
34. Acid inhibition in GERD-how much is enough?
Achem SR
Am J Gastroenterol; 2004 Jun; 99(6):997-9. PubMed ID: 15180716
[TBL] [Abstract][Full Text] [Related]
35. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
Beaumont H; Boeckxstaens GE
Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
[TBL] [Abstract][Full Text] [Related]
36. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.
Sharma N; Agrawal A; Freeman J; Vela MF; Castell D
Clin Gastroenterol Hepatol; 2008 May; 6(5):521-4. PubMed ID: 18356117
[TBL] [Abstract][Full Text] [Related]
37. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy.
Bredenoord AJ; Weusten BL; Timmer R; Conchillo JM; Smout AJ
Am J Gastroenterol; 2006 Mar; 101(3):453-9. PubMed ID: 16464226
[TBL] [Abstract][Full Text] [Related]
38. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results.
Roman S; Serraj I; Damon H; Mion F
Neurogastroenterol Motil; 2007 Jul; 19(7):562-8. PubMed ID: 17593137
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
Bordin DS; Masharova AA
Eksp Klin Gastroenterol; 2008; (5):85-90. PubMed ID: 19145922
[No Abstract] [Full Text] [Related]
40. [pH-impedancemetry: clinical implications].
Bertolini D; Roman S; Dumonceau JM
Rev Med Suisse; 2008 Sep; 4(169):1873-4, 1876-8. PubMed ID: 18831408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
